Unimed AndroGelô AndroGelô is the first-ever testosterone replacement gel to be approved by the FDA for replacement therapy in men for conditions associated with low testosterone. Low testosterone, also known as hypogonadism, affects approximately four to five million American men. The condition is linked with diminished interest in sex, impotence, reduced lean body mass, decreased bone density and lowered mood and energy levels. AndroGelô will be available with a prescription in pharmacies throughout the United States by mid-summer. Unimed http://www.unimed.com/prodmark.html#androgel Andractimô Unimed is currently conducting phase III trials of Andractimô (dihydrotestosterone gel) to treat male hormone deficiency in mature men, a condition also known as geriatric hypogonadism, or "male menopause." This clear, odorless, non-irritating, aesthetically pleasing topical gel delivers dihydrotestosterone transdermally to the bloodstream. Dihydrotestosterone is a natural male hormone that recently has been shown to potentially reduce the risk of prostate disease, particularly benign prostatic hyperplasia (BPH) and prostate cancer. Between their late 40s and early 70s, men may experience a 30 to 40 percent decrease in testosterone levels. Untreated, this can lead to sexual dysfunction, loss of muscle mass, decreased bone density and depressed mood. The estimated market for geriatric hypogonadism is in excess of $1 billion. Unimed plans to submit a NDA for Andractimô in late 2001. Unimed also is evaluating Andractimô for treatment of BPH, a condition in which the prostate gland that surrounds the urethra benignly increases in size, leading to a restriction of urine flow. The market for this potential indication is enormous as the incidence of BPH rises steeply in men 50 and older. A patent for Andractimô use in BPH was issued in June 1998. Unimed http://www.unimed.com/prodinvest.html#dhtgel
	Unimed http://www.unimed.com
	[home] - [info.] - [links] - [list] - [e-mail] Arctic Fox DesignEmail: webmaster@ftminfo.net